Analyst consensus rating
Vertex Pharmaceuticals Analyst Rating: Buy
Direct answer
Vertex Pharmaceuticals's consensus rating is Buy.
27 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $569.19.
Forecast evidence checked September 21, 2026.
Get free Vertex Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $508.34
- Average price target
- $569.19
- High price target
- $672.00
- Low price target
- $350.00
- Low target gap
- -31.1%
- Target upside
- +12%
- High target gap
- +32.2%
- Target range width
- 63.3%
- Consensus rating
- Buy
- Analysts
- 27
- Evidence date
- September 21, 2026
- Valid through
- September 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Vertex Pharmaceuticals?
Vertex Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $569.19.
How far are Vertex Pharmaceuticals's low and high targets from the recorded price?
The low target implies -31.1%, while the high target implies +32.2%.
How many analysts are included in Vertex Pharmaceuticals's consensus?
The verified consensus includes 27 analysts.
How is Vertex Pharmaceuticals's target upside or downside calculated?
The average target of $569.19 is divided by the recorded price of $508.34, then one is subtracted to produce +12%. This does not guarantee a future return.
When was Vertex Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-09-21. The dataset is valid through 2026-09-28.